Pharmacological and pharmacokinetic features and clinical effects of pitavastatin

Folia Pharmacologica Japonica

Volumn 123, Issue 5, 2004, Pages 349-362

  Yamazaki, Hiroyuki ^a   Fujino, Hideki ^a   Kanazawa, Mizuho ^a   Tamaki, Taro ^a   Sato, Fumiyasu ^a   Suzuki, Mikio ^b   Kitahara, Masaki ^b  

^a KOWA COMPANY LTD   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Atherosclerosis; Drug interaction; HMG CoA reductase inhibitor; LDL receptor; Pitavastatin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 2C9; ERYTHROMYCIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICARDIPINE; PITAVASTATIN; SIMVASTATIN; STATINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BILE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; GRAPEFRUIT JUICE; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; LIVER; PRESCRIPTION; REVIEW; SIDE EFFECT;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, VLDL; CITRUS PARADISI; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FOOD-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROCETOFEN; QUINOLINES; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 2442658201     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.123.349     Document Type: Review

References (51)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-1307.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97:1440-1445.
4. Vance DE, Van den Bosch H. Cholesterol in the year 2000. Biochim Biophys Acta. 2000;1529:1-8.
5. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131.
6. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285-288.
7. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
8. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.
9. Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000;150:121-127.
10. Suzuki M, Yanagawa Y, Iwasaki H, et al. First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104. Bioorg Med Chem Lett. 1999;9:2977-2982.
11. Suzuki M, Iwasaki H, Fujikawa Y, Kitahara M, Sakashita M, Sakoda R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg Med Chem. 2001;9:2727-2743.
12. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 1997;47:904-909.
13. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232:34-47.
14. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999;96: 11041-11048.
15. Nakagawa S, Tanabe S, Tamaki T, et al. Effect of NK-104, an HMG-CoA reductase inhibitor on lipid metabolism in HepG2 cells. Jpn Pharmacol Ther. 2001;29:51-57.
16. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138-144.
17. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis. 1999;146:259-270.
18. Suzuki H, Yamazaki H, Aoki T, et al. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Arzneimittelforschung. 2001;51:38-45.
19. Huff MW, Burnett JR. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol. 1997;8: 138-145.
20. Yanagita T, Hara E, Yotsumoto H, et al. NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Curr Ther Res. 1999;60:423-434.
21. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687-695.
22. Kitahara M, Kanaki T, Toyoda K, et al. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Jpn J Pharmacol. 1998;77:117-128.
23. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K. Plaque-stabilizing effect of pitavastatin in Watanabe Heritable Hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb. 2003;10:109-116.
24. Morikawa S, Takabe W, Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb. 2002;9(4):178-183.
25. Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90(1):23-32.
26. Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica. 2001;31:499-538.
27. Fujino H, Kojima J, Yamada Y, et al. Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Xenobio Metabol Dispos. 1999;14:79-91.
28. Kojima J, Ohshima T, Yoneda M, Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin in dogs. Xenobio Metabol Dispos. 2001; 16:497-502.
29. Kimata H, Fujino H, Koide T, et al. Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metabol Dispos. 1998;13:484-498.
30. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993;264:36-44.
31. Shimada S, Fujino H, Kojima J, et al. Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokin. 2003;18:245-251.
32. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase - effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metabol Pharmacokin. 2002;17:449-456.
33. Yamazaki M, Akiyama S, Sugiyama Y, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by cMOAT. Drug Metab Dispos. 1997;25:1123-1129.
34. Fujino H, Saito T, Tsunenari Y, et al. Interaction between several medicines and statins. Arzneimittelforschung. 2003;53:145-153.
35. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27-41.
36. Christians U, Jacobsen W, Floren L. Metabolism and drug interactions 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: are the statins mechanistcally similar? Pharmacol Ther. 1998;80:1-34.
37. Prueksaritanont T, Subramanian R, Fang X. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30:505-512.
38. Jacobsen W, Kuhn B, Soldner A. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atrovastatin. Drug Metab Dispos. 2000;28:1369-1378.
39. Geriat Med. 2001;39:849-860.
40. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122-129.
41. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-75.
42. Fukuda K, Ohta T, Ohshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics. 1997;7:391-396.
43. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol Pharm Bull. 1998;21:1062-1066.
44. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther. 1999;66:118-127.
45. Tomlinson B. Medical View Point. 2003; 24(11):4.